These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 16128893

  • 1. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM).
    Parti R, Schoppmann A, Lee H, Yang L.
    Haemophilia; 2005 Sep; 11(5):492-6. PubMed ID: 16128893
    [Abstract] [Full Text] [Related]

  • 2. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA, Evans MA, Skaer TL, Robison LM, Chung KC, Poulios NS.
    Drugs R D; 2005 Sep; 6(3):149-56. PubMed ID: 15869318
    [Abstract] [Full Text] [Related]

  • 3. Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.
    Fernandez M, Yu T, Bjornson E, Luu H, Spotts G.
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):165-71. PubMed ID: 16575253
    [Abstract] [Full Text] [Related]

  • 4. Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81-8973 compared with other full-length rFVIII products.
    Teare JM, Kates DS, Shah A, Garger S.
    Drug Des Devel Ther; 2019 Apr; 13():941-948. PubMed ID: 30962676
    [Abstract] [Full Text] [Related]

  • 5. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V.
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [Abstract] [Full Text] [Related]

  • 6. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
    Kitchen S, Beckmann H, Katterle Y, Bruns S, Tseneklidou-Stoeter D, Maas Enriquez M.
    Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
    [Abstract] [Full Text] [Related]

  • 7. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM, RAHF-PFM Clinical Study Group.
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [Abstract] [Full Text] [Related]

  • 8. In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.
    Nedergaard H, Vestergaard S, Jensen PT, Kristiansen MW, Jensen MB, Ostergaard PB, Norsell T, Bjerre J.
    Clin Ther; 2008 Jul; 30(7):1309-15. PubMed ID: 18691990
    [Abstract] [Full Text] [Related]

  • 9. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A, Solms A, Garmann D, Katterle Y, Avramova V, Simeonov S, Lissitchkov T.
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [Abstract] [Full Text] [Related]

  • 10. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S, Núñez R, Poveda JL, Kurnik K, Goldmann G, Andreozzi V, Vandewalle B, Santos S.
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [Abstract] [Full Text] [Related]

  • 11. Development of freeze-dried biosynthetic Factor VIII: I. A case study in the optimization of formulation.
    Jameel F, Tchessalov S, Bjornson E, Lu X, Besman M, Pikal M.
    Pharm Dev Technol; 2009 Sep; 14(6):687-97. PubMed ID: 19883259
    [Abstract] [Full Text] [Related]

  • 12. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.
    Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J.
    J Blood Med; 2016 Sep; 7():129-37. PubMed ID: 27445511
    [Abstract] [Full Text] [Related]

  • 13. In vitro stability of recombinant human factor VIII (Recombinate).
    Parti R, Ardosa J, Yang L, Mankarious S.
    Haemophilia; 2000 Sep; 6(5):513-22. PubMed ID: 11012695
    [Abstract] [Full Text] [Related]

  • 14. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
    Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED.
    Semin Hematol; 2004 Jan; 41(1 Suppl 2):1-16; discussion 16-8. PubMed ID: 15071785
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
    Chen R, Gultyaev D, Lister J, Han R, Hu N, Malacan J, Solms A, Vashi P, O'Hara J, Hu S.
    BMC Med Res Methodol; 2022 Aug 05; 22(1):215. PubMed ID: 35931967
    [Abstract] [Full Text] [Related]

  • 16. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, Schroth P, Ewenstein B.
    Thromb Haemost; 2008 Aug 05; 100(2):217-23. PubMed ID: 18690340
    [Abstract] [Full Text] [Related]

  • 17. B-domain deleted recombinant factor VIII formulation and stability.
    Osterberg T, Fatouros A, Neidhardt E, Warne N, Mikaelsson M.
    Semin Hematol; 2001 Apr 05; 38(2 Suppl 4):40-3. PubMed ID: 11449334
    [Abstract] [Full Text] [Related]

  • 18. Impact of residual moisture and formulation on Factor VIII and Factor V recovery in lyophilized plasma reference materials.
    Hubbard A, Bevan S, Matejtschuk P.
    Anal Bioanal Chem; 2007 Apr 05; 387(7):2503-7. PubMed ID: 17072599
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
    Pollmann H, Klamroth R, Vidovic N, Kriukov AY, Epstein J, Abraham I, Spotts G, Oldenburg J.
    Ann Hematol; 2013 May 05; 92(5):689-98. PubMed ID: 23324986
    [Abstract] [Full Text] [Related]

  • 20. Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free.
    Drugs R D; 2003 May 05; 4(6):366-8. PubMed ID: 14584967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.